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Abstract: Nowadays the most important problem in the treatment of bacterial infections is
the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR
(pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is
renewed interest in revisiting the use of bacteriophage to treat bacterial infections. The
practice of phage therapy, the application of phages to treat bacterial infections, has been
around for approximately a century. Phage therapy relies on using lytic bacteriophages and
purified phage lytic proteins for treatment and lysis of bacteria at the site of infection.
Current research indicates that phage therapy has the potential to be used as an alternative
to antibiotic treatments. It is noteworthy that, whether phages are used on their own or
combined with antibiotics, phages are still a promising agent to replace antibiotics. So, this
review focuses on an understanding of challenges of MDR, XDR, and PDR bacteria and
phages mechanism for treating bacterial infections and the most recent studies on potential
phages, cocktails of phages, and enzymes of lytic phages in fighting these resistant bacteria.
Keywords: bacteriophage, drug resistant, MDR, XDR, PDR
Introduction
Reports of scientific studies suggest that the development of antibacterial drugs is
lagging behind the emergence of antibacterial resistance profile, especially for
major bacterial pathogens.1,2 Several antibacterial resistance profiles have been
detected recently including the multidrug-resistant (MDR), extensively drug-
resistant (XDR) and pan drug-resistant (PDR) phenotypes.3–6 Accordingly, the
human health and efficiency of commonly used antibiotics are threatened seriously
by MDR and XDR bacteria. Studies showed that at least 25,000 patients die
each year in the European hospitals from an infection due to MDR bacteria.1–6
Furthermore, the mortality rate for patients infected by XDR organisms is reported
to be over 50 percent, which has led to increased healthcare costs.1,2,4–6 The
impacts of resistant infections to healthcare costs are estimated at about $
20 billion yearly and they also result in 8 million additional hospital days in the
United States.7–9 Furthermore, over 30 percent of pharmaceutical budgets of hos-
pitals in the United States is spent on antibiotics. Methicillin-resistant
Staphylococcus aureus (MRSA) is an antibiotic-resistant agent, which poses
a remarkable threat to the health care by causing ~19,000 deaths and a cost of
$3-4 billion annually in the US. The number of cases influenced by MDR, XDR,
and PDR Gram-negative bacteria, such as Acinetobacter baumannii, Escherichia
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, as well as MDR or XDR
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isolates of Mycobacterium tuberculosis has been growing
continuously in recent years. The inherent genetics and
physiology transmitted vertically across species, and the
bacteria’s tendency for exchanging different genes hori-
zontally among species and genera have been suggested as
the possible causes of antibiotic resistance in these
bacteria.7–9 The limitation of current clinical options for
confronting threats of infections caused by intricate patho-
gens has led to a critical problem that promotes research-
ers to discover new approaches to face the growing
problem of bacterial MDR, XDR, and PDR. Although
different management strategies have been implemented
for combating resistant pathogens, such as (a) comprehen-
sive understanding of the nature of resistance in terms of
molecular basis, evolution, and dissemination; (b) finding
new chemical agents that have antibiotic properties; and
(c) enhancing the efficiency of antibiotics using innovative
techniques, such as combination therapy, increasingly
resistant bacteria are on the rise. Accordingly, alternative
approaches are required to control resistant pathogens.
Bacteriophage (phage) is an example of such management
strategies.10–13 Bacteriophages are specific viruses natu-
rally influencing the bacteria that have been used as ther-
apeutic agents for bacterial infections. Using phages as
antibacterial agents for pathogenic bacteria, known as
phage therapy, was first introduced approximately 90
years ago. The basis of this treatment is binding of
a phage to bacterial cells and causing rapid lysis of the
cells.14 Considering the background of rising antibiotic
resistance and decreasing number of new antimicrobial
components, phage therapy as a novel safe strategy
seems attractive for the following reasons: the phage and
antibiotic resistance have different mechanisms of action;
their effects are limited to the site of infection with no
effect on their surrounding cells such as eukaryotic cells,
and they can be easily isolated from several
environments.14 In the last decade, supporting evidence
is provided worldwide to help establish the efficacy of
bacteriophages in combatting the challenges posed by
MDR, XDR, and PDR bacteria, and even show the ability
of bacteriophages to replace antibiotic treatments.15–18
This review focuses on the challenges in the conventional
treatment of MDR, XDR, and PDR bacteria and the
mechanisms by which phages may help to treat such
infections. The most recent studies on the potential of
phages, phage cocktails, and the enzymes of lytic phages
in fighting these resistant bacteria are included in this
review.
History of Phage Therapy
The presence of a biological source in the water of an Indian
river that changes the cultures of cholera-inducing bacteria
was first discovered in 1896 by a British bacteriologist,
Ernest Hanbury Hankin.19 His experiment may be the first
discovery of bacteriophage activity. The probable destruction
of bacteria into granules through transparent materials pre-
sent in pure cultures was later realized by Frederick Twort
while he was working on the growth of vaccinia virus.20
Further supporting reports for these experiments were pro-
vided by Felix d’Herelle who described his finding as “anti-
Shiga microbe” which was detected during filtering stools of
patients suffering shigellosis. Twort and d’Herelle were cur-
ious about the agent causing bacterial lysis and questioned if
the destroying agent was a bacterial virus. However, at the
time, d’Herelle believed that the observed microbe was
a “veritable” microbe of immunity and an obligate
bacteriophage.21 Unfortunately, Twort was not able to con-
tinue his investigation in this field, because of some reasons,
such as funding shortages and his enrolment in the Royal
ArmyMedical Corps. Nevertheless, d’Herelle started to treat
bacterial infections in humans, which resulted in publication
of many articles based on non-randomized trials worldwide.
Then, he recommended intravenous phage for the treatment
of invasive infections and presented a summary of all his
findings and observations in 1931.21–23 Following these
works, the idea of phage attracted the microbiologists’ atten-
tion and soon the phage therapy played a pivotal role in the
development of medicines. Tracing the progression of phage
biology shows that this field started with an enthusiastic
period associated with excessive and often unrealistic claims
with a limited understating of the viral nature of phages or
their strengths and limitations.24,25 Phage therapy and its
active application continued to develop in the Soviet Union
and Eastern Europe in the 1940s. In the West, the develop-
ment of molecular biology based on phage therapy in its
golden age was limited to the intensive work on just a few
phages infecting a virulent strain of E. coli.14,26 Finally,
thanks to the invention of the electron microscope, Helmut
Ruska, a German doctor, was able for the first time to
describe both round and “sperm-shaped” particles from
a phage suspension adhered to a bacterial membrane.
Various stages of bacterial lysis including adsorption, vast
bacterial destruction, and development of many newly
formed bacteriophages were also described.14,27 The findings
of some studies showed the usefulness of bacteriophages in
the treatment of various infections, including S. aureus and
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P. aeruginosa, but due to some limitations of these publica-
tions, such as lacking control groups and being conducted in
a small area, they failed to assure the rest of the world about
the effectiveness and safety of this agent.14,28–30 In the last
two decades, scientists faced the emergence of MDR, XDR,
and PDR bacteria and the slow development of new antibio-
tics refocused on bacteriophages. Recently, encouraging
results comes from some well-designed clinical trials, con-
ducted mainly on wound infection in burn patients, ulcers
and chronic otitis. The bacteriophages have become such
interesting agents that are amongst the weapons for fighting
against antibiotic resistance in the US. Use of bacteriophage
in recent insightful research, against MDR, XDR, and PDR
bacteria, might be relevant to therapies against S. aureus,
P. aeruginosa, A. baumannii, and infectious diseases.18,31
Why Would We Need Phage
Therapy?
In 1943, more than 10 years after its discovery by
Alexander Fleming (1928),32 penicillin offered a cure for
infectious diseases for the first time and became a pioneer
in the treatment of infectious diseases. Thereafter, other
antimicrobials including widely used antibiotics, such as
streptomycin, chloramphenicol, and tetracycline were dis-
covered. Accordingly, the role of antibiotics in the treat-
ment and prevention of infections, especially during World
War II was realized. Based on these facts, a world without
antibiotics seems unrealistic. Although antibiotics were
initially successful, the production of new antibiotics was
unable to keep up with the increasing incidence of infec-
tions caused by antibiotic- resistant bacteria and growing
rate of antibiotic resistance.
However, the production of new antibiotics is no
longer cost-effective, because of the development of resis-
tance to antibiotics immediately after their production.33,34
So, the available options for treatment of major MDR
bacteria, such as Enterococcus faecium, S. aureus,
K. pneumoniae, A. baumannii, P. aeruginosa, and
Enterobacter were so limited that an urgent need for dis-
covery of alternative antibiotics to fight antibiotic-resistant
infections was felt.27 Using of bacteriophage as a natural
and non-conventional antimicrobial agent in this period of
progressive spread of MDR, XDR and PDR bacteria with
a paucity of new antibiotics presents a new solution. Today
it may be possible to successfully use bacteriophages as
described in various cases including food safety, agricul-
ture, veterinary applications, detection and control of
foodborne pathogens, industry, the therapeutic use of
phage, and clinical diagnostic, such as detection and typ-
ing of bacteria in human infection. They have special
characteristics, such as bactericidal effect, low inherent
toxicity, high selectivity, lack of cross-resistance with anti-
biotic classes as well as self-multiplication in the presence
of the bacterial host that distinguish them from conven-
tional antibiotics.18,27,33,35–37 Also, unlike broad-spectrum
antibiotics, phage spare the commensal microbiota due to
their strain-specific activity, which is particularly impor-
tant for malnourished and immunodeficient people.
Eventually, they can be prepared in dry powder formula-
tions that do not require a cold chain.38 According to the
aforementioned features, it seems that phage therapy pro-
vides the greatest hope for infectious diseases compared to
antibiotics in the future.
Major Advantages of Phage Therapy
Phage therapy boasts many advantages over traditional
antibiotics (Table 1). Bacteriophages are natural antibio-
tics that are able to work against Gram-positive and
Gram-negative bacteria.39,40 Phages can be isolated
rapidly, because of their ubiquitous nature and they are
abundant in every ecological niche, which reduces their
development costs compared to antibiotics. Accordingly,
in an environment containing a certain pathogen, there is
a high probability for the presence of specific phages for
that microorganism. The phages can be isolated from
various environments, such as soil, water, sewage efflu-
ent, hospital effluent, hot springs, and fecal material, and
also humans and animals gastrointestinal tracts.41 It is
hard to evaluate the side effects and potential impact of
phages, but they appear to be relatively free of side-
effects due to daily contact between humans and phages
which may explain why no adverse effects have been
detected in humans.42 The advances in diagnostic tools
and technologies during the last decades have introduced
phages as an appropriate option for the diagnosis of the
bacteria involved in infections. The bacteriophage is
widely used in food preservation for extending the shelf
life of refrigerated processed foods ready for consump-
tion for example to the surfaces of preserved meats and
cheeses.42 Phage therapy may have an impact on the
inflammatory response to the infection, decrease in
mean C reactive protein values and leukocyte counts,
with a similar tendency of erythrocyte sedimentation
rate, an effect that can be one of the most promising
aspects of phage therapy.43 An important characteristic of
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phages is their high host specificity, which is usually at
the species or strain level. This characteristic reduces the
damage to the normal microbial community, in contrast
to antibiotics that reduce normal flora and consequently
can lead to super-infection and other complications.44
The concentration of phages increases at the site of
infection, because of their innate self-replicating property.
So, the presence and persistence of phages avoid the
potential overgrowth of the secondary pathogen which,
in turn, lowers the need for multiple doses to cure infec-
tious diseases and eventually enhances the efficacy of
treatment. In addition, the fast distribution of phages all
over the body makes them available to the organs (such
as prostate gland, bones, and brain) that are not readily
accessible by drugs and their replication in the presence
of their hosts enables them to treat infections that other-
wise evade treatment. Another advantage of phages is the
absence of cross-resistance to antibiotics and mechanisms
developed by bacteria to resist antibiotics that prevent
interference with phage efficacy, therefore phages are
considered as an effective solution against MDR, XDR,
and PDR bacteria.18,27,45 When a bacterium develops
resistance to a particular phage, it will remain sensitive
to phages with different cell surface receptors, such as
receptors specific to lipopolysaccharides, proteins, tei-
choic acids.46 So, using a cocktail of phages has some
advantages such as the higher impact on targeted bacteria
and a lower probability of development of phage-resistant
bacteria due to the presence of different types of phages
infecting the same species and strains.44
How Phages Lyse Bacterial Host
Cells
The replication cycle is a prerequisite for the production of
bacteriophage particles. If the infected cells release the
lytic phage, their bacterial hosts will be lysed.47
Accordingly, phages use a single protein called amurins
for bacterial lysis, which inhibits peptidoglycan (PG)
synthesis or they can use holin–lysin systems.24,47,48 The
holins cause large pores in the cytoplasmic membrane that
provides pathways, through which endolysins release to
the cell wall and results in rapid cleavage of several bonds
of the PG meshwork and consequently influence the phy-
sical integrity of the bacterial cell wall.49,50 Based on the
difference in the amino acid sequence, holins are divided
into class 1, 2, and 3 and S. aureus bacteriophage p68
hol15 protein, Lambdoid phage 21 S protein and phage
ACP26F holin fall into these classes, respectively.49–51 On
Table 1 Advantages and Disadvantages of Using Phage Therapy in the Treatment of Bacteria
Advantage Disadvantage
● Active against gram-positive and gram-negative ● Bacteria are able to develop resistance against phages
● Rapid isolation and lower development costs ● When the target organism is not present the phages will not replicate
● Relatively free of side-effects ● Phages may carry antibiotic-resistance genes or bacterial virulence
factors
● Widely used in food preservation ● Phages are perceived by the immune system as invaders and can be
rapidly removed
● Disrupt bacterial biofilms, MDR, and XDR ● There are no clear official guidelines
● Phage therapy can affect the immune system with functions such
as decrease in mean C reactive protein values and leukocyte
counts
● Phage rapidly can lyse bacteria that may lead to the release of endo-
toxins and super antigens and induce an inflammatory cascade leading
to multiple organ failure
● Reduces the damage caused to the normal microbial community ● The genome of the majority of phages has been unraveled and the
function of many of these genes is still unknown.
● Avoids the potential overgrowth of the secondary pathogen ● It is difficult to extrapolate from in vitro phage growth data to in vivo
prospect
● Rapidly distribute throughout the body ● The phage specificity for bacterial host causing needs to exact host
bacterium be identified
● Absence of cross-resistance to antibiotics ● lytic phages should be used exclusively
● Recognizing different cell surface receptors
● Cocktail of phages has some advantages, such as the higher impact
on targeted bacteria
● Diagnosing an infectious agent in clinical microbiology laboratories is
very time-consuming for using specific bacteriophage solution for
patient
● Phage treatment is not covered by public health insurance
● Phages are not accepted as pharmaceutical drugs
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the other hand, phage endolysins destroy the cell walls
through the hydrolysis of peptidoglycans. Furthermore,
endolysins mimic the activities of endopeptidase, amidase,
glycosidase or lytic transglycosylase for killing bacterial
cells via murein destruction, and they enhance the diffu-
sion of progeny virions at the end of the phage replication
cycle.52,53 Evidence shows that several phages have the
ability to release their endolysins to the extracytoplasmatic
medium of the host cells through engaging the host cells’
secretion machinery, particularly the general secretion
pathway (Sec system), before the viral reproductive cycle
is completed.54 However, it should be noted that these
enzymes are transmitted to the cell wall during phage
development, but the host cell lysis does not occur until
the end of the lytic cycle. In fact, lysis timing happens
when holins, directly or indirectly, abolish the mechanisms
that restrain the activity of the secreted endolysins. For
example, in some phages, holins can stimulate the host’s
autolytic activity by their membrane-depolarizing func-
tion, and also trigger virion progeny release.55,56 To help
this process, an antiholin-like protein, has the ability to
tune the timing of the holin action in response to environ-
mental cues, while spanins and lipases weaken the outer
membrane barrier of Gram-negative hosts bacteria and
compromise the mycolyl-arabinogalactan external layer
of the mycobacterial cell envelope respectively.55 In
addition, phages can interfere with the production of var-
ious proteins for key host processes, which can ultimately
cause them to die. For example, in a study on pseudomo-
nas spp, it was observed that proteins produced by various
phages can interfere with the various functions of this
bacteria, including cell transcription and translation,
RNA degradation, cellular motility, metabolism, clustered
regularly interspaced short palindromic repeats (CRISPR)-
mediated immunity to phages and phage DNA silencing.57
There are some studies on how phages lyse bacterial host
cells, yet there is a need for a better understanding of their
mechanisms in order to use phages to eliminate multi-drug
-resistant bacteria, as alternatives to the antibiotics
(Figure 1).
Delivery Routes for Phage Therapy
in Animal Models
Bacteriophages can be delivered through different routes;
including gastrointestinal, parenteral, topical, and inhalation.
Lytic bacteriophages have also been considered for fighting
MDR and XDR bacteria as well as biofilm formation on
indwelling medical devices.38,58–60 Animal studies have con-
firmed that parenteral delivery, in which the phages are
immediately diffused into the systemic circulation, is one of
the most general and prosperous delivery methods for bacter-
iophages therapy. Therefore, recent reports have highlighted
Figure 1 A schematic representation of a bacterial cell, with the different cellular processes that are influenced by phage or phage proteins. 1; CRISPR 2; RNA Polymerase 3;
Metabolism Pathway 4; Peptidoglycan 5; Flagella 6; pili 7; DNA 8; Ribosomes 9; RNA degrade 10; Sec Secretion System.
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that the specific sites of administration, such as intramuscu-
lar, subcutaneous or intraperitoneal (IP) administrations have
a significant effect on the success of phage therapy. To
develop and experiment a customized therapeutic phage for
treatment of an MDR A. baumannii wound infection,
a cocktail containing five members of wild phages was
used by Regeimbal et al Phage treatments was followed by
IP and topical administration of 4 × 109 PFU of phages
preparations and 5 × 109 PFU of phages in PBS topically
under the Tegaderm dressing, on top of the wound. When
wound therapy performed, it was confirmed that the signifi-
cance of anticipating population changed during phage ther-
apy and designing intelligent cocktails controlled emergent
strains, so wounds began to heal and wound size decreased
after day 13.61 In a similar study conducted by Vieira et al,
a skin infection was induced in mice by IP injection of MDR
P. aeruginosa. This study indicates that the phage PA709 can
significantly inactivate MDR P. aeruginosa in its topical
application. For some reasons, such as good performance in
the inactivation of MDR P. aeruginosa and its effectiveness
on a remarkable range of hosts, phage therapy is suggested as
a very promising approach for the treatment of P. aeruginosa
skin infections.60 The use of lytic enzymes of phage against
antibiotic-resistant Streptococcus pneumoniae infection in
a murine sepsis model was tested by Jado et al as a new
therapy. The results of this study demonstrated that a single
IP injection was sufficient for the effective protection of the
mice. Regarding the bacteremia, they found that the mean
colony count in lysin-protected animals was <106 colony
forming unit (CFU)/mL and it reduced gradually over time
to an undetectable level while in unprotected mice the colony
counts reached >107CFU/mL.62 Furthermore, bacteriophage
therapy was examined in the clinical isolates of vancomycin-
resistant E. faecium by IP injection of 109CFU, which res-
cued mice by inducing bacteremia. Although the fatal effect
of bacteremia appeared within 48h, a single IP injection of 3
× 108 plaque-forming unit (PFU) of the phage strain was
sufficient to rescue 100% of the animals. Even in animals that
were moribund, because of delayed treatment, a single injec-
tion of this phage preparation could rescue nearly 50% of
them.63 The rescue of septicemic mice infected by MDR
P. aeruginosa using lytic bacteriophages was evaluated by
Vinodkumar et al IP injection of 107 CFU of MDR
P. aeruginosa was applied for inducing septicemia in mice.
In this study, a phage strain with the lytic activity against
many types of clinical isolates of MDR P. aeruginosa was
used. A single IP injection of 3 × 109 PFU of the phage
strain was adequate for saving all of the animals.64 In another
study, the effect of phage therapy on antibiotic resistant
Mycobacterium avium infection was evaluated in -
vivo. M. avium was used to create an infection and 7 days
later, the infected mice were treated once or twice with TM4
phage (7.9 ×1010 PFU/mL) intravenously. After treatment,
the number ofM. avium in the spleen decreased significantly
under the effect of TM4 phage, however, 23% of recovered
bacteria from treated mice developed resistance to TM4.65
The effect of 1.0 mg bacteriophage lysin administered by IP
injection on controlling MDR A. baumannii sepsis, and bio-
film formation on catheters and the joint was examined in
mice. A marked decline in total biofilm biomass on the
catheters was observed, which was confirmed using scanning
electron microscopy. Moreover, the survival rate of the mice
infected with this highly lethal dose of A. baumannii in their
systemic circulation increased up to 50% after the
treatment.39 Bacteriophages were also used to protect mice
against a lethal XDR A. baumannii infection in a study
described by Deng et al Mice in the sepsis control group,
antibiotics treatment group, and phage treatment group were
injected with 1 mL XDR A. baumannii. A slightly higher
survival ratio of mice was observed in the phage treatment
group compared with the antibiotics treatment group.66
Morello et al used an MDR P. aeruginosa mucoid strain
isolated from a cystic fibrosis patient to develop a mouse
lung-infection model. The intranasal route was selected to
deliver bacteria and bacteriophages to the immunocompetent
mice. To investigate bacteriophage P3-CHA effects, a four-
day preventive treatment protocol was used in which one
single dose rescued 100% of infected mice.67 Based on the
above reports, phage therapy should be considered as a viable
alternative for the treatment of bacterial infections in the
future due to its specificity and lack of side effects.
Phage Therapy in Humans
In recent years, phages have been used to treat various
infections caused by bacteria such as S. aureus, P.
aeruginosa, A. baumannii and E. faecalis. Phage ther-
apy in these studies has usually been applied following
treatment failures with antibiotics and good results
have been obtained with phages. In a study performed
on a 68-year-old diabetic patient with necrotizing pan-
creatitis complicated by an MDR A. baumannii infec-
tion, it was reported that 9 different lytic phages were
used because of the resistance of A. baumannii isolated
from this patient to different antibiotics. These phages
were administered percutaneously and intravenously
into the abscess, which cleared the infection and
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improved the patient’s condition.68 Ooi et al used
phage cocktail AB-SA01 to treat chronic rhinosinusitis
caused by the MDR S. aureus. The administration of
multiple intranasal doses of phage resulted in
a successful treatment without any adverse effects
which implied that this treatment could be an alterna-
tive to antibiotics.69 In another study, staphylococcal
phage Sb-1 was used for the treatment of ulcers in
diabetic patients, and the results showed that the topi-
cal use of a staph mono-phage preparation could
improve the infection even if the antibiotic treatment
had failed.70 Furthermore, bacteriophage OMKO1 was
used by Chan et al for the treatment of an aortic graft
infected by P. aeruginosa, since antibiotic treatment is
usually not practical in this situation. Their results
showed that phage and ceftazidime improved the infec-
tion and there were no signs of recurrence. In this
study, they directly reached the Perigraft collection in
front of the aortic root by needle puncture using image
guidance.71 Another case study demonstrated that intra-
venous bacteriophage cocktail BFC1 monotherapy can
be used to treat P. aeruginosa septicaemia in humans.72
Finally, in another study, phage was used to treat pros-
tatitis caused by E. faecalis, in which the rectal appli-
cation of phage lysates was used to access tissue and
inject phages. The results showed the elimination of
the infection, the improvement of the patients’ condi-
tions and the lack of early disease recurrence. It should
be noted that the use of antibiotics, autovaccines, and
laser Biostimulation for the treatment of the patients
also failed.73 It needs to be pointed out that other
studies investigating the therapeutic effects of phages
on infections have reported no adverse effects for dif-
ferent phages.74,75 Therefore, due to the high inhibition
of different antibiotic-resistant bacteria and minor side
effects, phages can be suggested as a potential replace-
ment for antibiotic treatments.
Global Concern for MDR, XDR and PDR
Pathogens
Antimicrobial resistance is a growing global concern, and the
resistance of bacteria to conventional antibiotics leads to
10 million deaths each year. The widespread and incorrect
use of antibiotics over time has created various resistance
mechanisms in bacteria that lead toMDR.76 MDR organisms
are labeled as such, because of their in vitro resistance to
more than one antibiotic or a key antimicrobial agent.77,78
Also, a definition of MDR is described as the resistance to
three or more antimicrobial classes, but currently there is not
any consensus on a standard definition for MDR by the
medical community.79,80 Bacteria that are categorized as
XDR or extensive drug resistance, are those that are resistant
to all or nearly all approved antimicrobial agents.78,81 PDR is
a term that refers to bacterial isolates with resistance to all
approved effective antibiotics for empirical treatments.82,83
Antibiotic resistance in Gram-negative bacteria is higher due
to the presence of outer membranes and defense agents, such
as the efflux pumps compared to Gram-positive bacteria.
Therefore, finding an effective strategy to control antibiotic
resistance, prevent its spread and develop new antibiotics
against Gram-negative bacteria is more difficult than against
Gram-positive ones.84,85 Different studies in recent years
have shown that Gram-positive and Gram-negative bacteria,
such as vancomycin-resistant enterococci, methicillin-
resistant S. aureus (MRSA), Enterobacteriaceae with
extended-spectrum b-lactamase and XDR A. baumannii
and P. aeruginosa have caused the highest mortality among
infected patients.86,87 On the other hand, it should be noted
that of extensively drug-resistant tuberculosis (XDR-TB),
MDRClostridium difficile and newly identified transmissible
carbapenamase, New Delhi metallo-betalactamases (NDM)
in Enterobacteriaceae are expanding all over the world, espe-
cially in developing countries, and may become a big pro-
blem in the coming years.3,88,89 Intrinsic properties, such as
external barriers, which prevent the entry of drugs into bac-
teria, natural mutations in antibiotic targets and acquired
features, such as sequestration of the drug, efflux pumps
and enzyme-dependent drug alterations cause such high
levels of resistance to existing antibiotics.11 Genetic trans-
mission of resistance agents by plasmids, integrons, transpo-
sons, and other mobile genetic elements, in addition to
widespread antibiotic resistance, also transforms commensal
bacteria into pathogens.90 Infection with bacteria with high
levels of resistance increases hospitalization time, delays the
treatment process, requires the use of more toxic antibiotics,
raises therapeutic costs, and brings many other problems for
patients.91,92 In 2005 almost 19,000 patients died in the
United States from MRSA infection, which is even higher
than annual deaths due to AIDS.93 So, there is an obvious and
essential medical need for a new approach for treating infec-
tions caused by MDR, XDR and PDR pathogens. The use of
antibiotic combinations and the development of new anti-
biotics are the current strategies for the treatment of MDR
bacterial infections, however, the poor success rate has dam-
pened interest. So, non-antibiotic remedies to cure bacterial
Dovepress Taati Moghadam et al
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infections are now under serious consideration and using
a specific phage that targets bacterial pathogen is suggested
as a preferable, potential choice for substitution to other
failed treatments.13,94
Bacteriophage for the Treatment of
MDR, XDR, and PDR Bacteria
Recent investigations using in vivo and in vitro conditions
have introduced the phages as a new treatment against
a range of clinically significant pathogens. When challenges
occurred with MDR S. aureus, the bacteriophage ϕMR11
lysed cells of a number of S. aureus in a fast and complete
manner in the growing condition, and also, effectively eradi-
cated MRSA that had been artificially inoculated into the
nares of mice.95 Three phages including SL1, SL2, and SL4
with the lytic activity that were collected from hospital sew-
age were applied against clinical isolates of MDR
P. aeruginosa. To rescue planktonic cells of MDR
P. aeruginosa strains, a single phage strain of that three
selected ones was adequate. The SL2 was the most potent
in suppressing planktonic cultures, however, the greatest
anti-biofilm activity was observed with SL4 in vitro condi-
tion. No synergistic and no antagonistic effects of a cocktail
was found with the three phages, however, the three-phage
cocktail was as effective as the best phage alone.96 Various
studies demonstrated that different bacteriophages were able
to reduce and lyse MDR P. aeruginosa in animal and in vitro
conditions.64,97,98 Additional animal studies show similarly
promising results for MDR E. coli O25:H4-ST13, Vibrio
parahaemolyticus, and S. aureus.99–101 There is even an
indication that the phages containing WP1, WP2, WP3,
WP4, and WP5 are capable of lysing antibiotic-resistant
bacteria, as in the case of MDR and XDR P. aeruginosa.102
After an in vitro investigation, it was realized that phage
ϕkm18p is able to effectively lyse the most XDR
A. baumannii and also using of phages as a cocktail has the
potential of lysing XDR A. baumannii isolates of all various
genotypes.45 The effect of ϕKMV, ϕPA2, ϕPaer4, and
ϕE2005 phages on 11 strains of MDR, and 1 strain of XDR
were tested by Abigail and et al. The results demonstrated
that phages were able to lyseMDR P. aeruginosa and prevent
biofilm formation, however, no effect on XDR P. aeruginosa
lysis was detected.17 A study that investigated the effect of
phages on widely drug-resistant A. baumannii in an animal
model demonstrated that the survival ratio of mice with
systemic infection increased more in the phage treatment
group than that of the antibiotics treatment group.
Furthermore, the inflammation responses were significantly
controlled by phages, and they effectively cleaned bacteria in
lung, liver, spleen, and kidney in mice with XDR
A. baumannii.66 The isolated bacteriophage vB_AbaM-
IME-AB2 was able to adsorb its host cells, and among the
22 clinical strains of MDR A. baumannii, only three strains
were affected and lysed by the phage.103 Effects of three lytic
phages, individually or combined in a cocktail, against XDR
and MDR P. aeruginosa suggested that they were highly
susceptible to at least one phage, as well as to the cocktail,
and there was a relation between genotype and the suscept-
ibility pattern.104 In another study, which was performed by
Lood et al, phage lysin was found to be capable of killing the
MDR A. baumannii clinical isolates in a mouse sepsis model.
Also, PlyF307 remarkably reduced the planktonic and bio-
film A. baumannii both in vitro and in vivo, which finally
rescued mice from lethal A. baumannii bacteremia.39 Phage
therapy was performed among 96 isolates of P. aeruginosa
composed of 2 non-MDR (2.1%), 94MDR (97.9%), 63 XDR
(65.6%), and 1 PDR (1.1%) isolates. The use of cocktails of
phages showed that they had activity against an extended
host range including all MDR, XDR, and PDR strains.105
The use of phage Abp1 against human cells and mice
infected by PDR A. baumannii demonstrated that Abp1 can
rescue HeLa cells from A. baumannii infection. In
A. baumannii infection in mice, Abp1 therapy, either local
or systemic, displays good therapeutic effects.18 Myoviridae
bacteriophage vB_AbaM_IME200 against PDR
A. baumannii was tested by Bai et al. The results demon-
strated that phage and its depolymerase had strong lytic
activity against PDRA. baumannii.106 Furthermore, the com-
bined use of phages and antibiotics has shown better effects
than antibiotic therapy alone, against biofilm and drug resis-
tant bacteria such as Burkholderia cepacia, P. aeruginosa,
E. coli, Klebsiella pneumoniae, E. faecalis, A. baumannii,
S. pneumoniae, and S. aureus in multiple studies.15,16,107–116
Some of phage therapy studies are summarized in Table 2.
Phage Resistance in Bacteria
Although phages are typically effective against antibiotic-
resistant bacteria, bacteria have acquired a significantly wide
array of sophisticated defense strategies to survive phage
infections (Table 3). Accordingly, the modes of action of
resistance to phages differs from those to antibiotics; never-
theless, several reports demonstrated that MDR, XDR, and
PDR bacteria are resistant to bacteriophages.45,117,118 These
mechanisms include endonucleases widely used as a part of
restriction-modification (R-M) systems, which can cleave
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Rashel et al95 2007 Japan Mice ϕMR11 MDR S. aureus Effectively eradicated MRSA into the nares
of mice
Latz et al96 2017 Germany In vitro SL1, SL2, and SL4 MDR P. aeruginosa Greatest anti-biofilm and planktonic cells
activity was observed
Golkar et al97 2013 USA Mice PS5 MDR P. aeruginosa Deep wound infection and chronic infection
treated the each of the infections by
respective dermal application of phages
Wang et al98 2006 China Mice ØA392 Imipenem-
resistant
P. aeruginosa
Protection from death occurred only in
animals inoculated with bacteria-specific
virulent phage strains
Pouillot et al100 2012 France Rat EC200PP MDR E. coli O25:
H4-ST131
In the sepsis model and meningitis model
phage rescued animals
Jun et al99 2014 Korea Mice pVp-1 MDR
V. parahaemolyticus
Phage-treated mice displayed protection
from a V. parahaemolyticus infection and
survived lethal oral and intraperitoneal
bacterial challenges




Phage prevented abscess formation in








Bacteriophages WP3, WP2 and WP5
exhibited the highest lytic activity against
P. aeruginosa strains





φkm18p XDR A. baumannii Phage φkm18p improved human lung
epithelial cells survival rates when they
were incubated with A. baumannii





Phages were able to lyse MDR P. aeruginosa
and prevent biofilm formation
Larché et al104 2012 France In vitro FrNa3 and FrNa9 XDR and MDR
P. aeruginosa
Bacteriophages were found to lyse 42 of the
44 analyzed strains
Shokri et al105 2017 Iran In vitro Psu1 and Psu2 MDR, XDR, and
PDR P. aeruginosa
Cocktails of phages had extended host
range activity against all MDR, XDR, and
PDR strains




Abp1 PDR A. baumannii Abp1 can rescue HeLa cells from
A. baumannii infection
Bai et al106 2018 China In vitro vB_AbaM_IME200 PDR A. bsaumannii Phage had strong lytic activity against PDR
A. baumannii





P. aeruginosa counts were significantly lower
only in the phage treated group and clinical
indicators improved for the phage treated
group relative to the placebo group.
(Continued)
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phage DNA. Development of adaptive immunity by interfer-
ing CRISPR sequences has results in degradation of the
injected phage DNA.117,119 There is clear evidence that
genetic mutations decrease bacterial virulence and spoil or
modify the molecules that the phage uses as receptors, since
bacterial receptors for phage adsorption are often virulent
determinants or crucial molecules to the bacterial cell. In
some instances, phage receptors may have phase variation
or hide behind a physical barrier, such as a capsule or other
extracellular polymer. These structures can elevate bacterial
survival in various conditions by protecting the bacteria
against harsh ecological niches and, sometimes, hindering
phages to find their receptors by providing a physical obsta-
cle between them.120,121 On the other hand, a minimum
population of bacteria that produces the receptor slowly and
at low levels determines the long period sustainability and
phage-resistant mutants can be efficiently isolated.122
Bacillus species were shown to exhibit antiviral effects
when producing RNase III and MazF and action of RNases
is more remarkable under starvation. Another agent with
anti-phage activity is secreted RNase of Bacillus with the
ability of interference with phage adsorption or causing
abortive infection.123 Super infection exclusion (Sie) systems
are proteins that prevent the phage DNA to enter into the
bacterial cytoplasm. These proteins are anchored to the mem-
brane or associated with its components. Sie systems are
associated with the prophages that are found in various
bacteria and the bacteria carrying lysogenic phage can pre-
vent subsequent infection by other phages. However, only
a few of these systems characterized in Gram-negative and
Gram-positive bacteria were reported.118,120 Bacteriophage
exclusion (BREX) is another new system of bacterial defense
in which the DNA methylation of the host cell blocks phage



















No significant difference (p>0.05) was
determined between the test and control
groups for frequency of adverse events, rate
of healing, or frequency of healing.
Jennes et al72 2017 Belgium Human BFC1 MDR P. aeruginosa
septicaemia
Not only blood cultures turned negative,
CRP levels dropped and the fever
disappeared but also kidney function
recovered after a few day.
Chan et al71 2018 USA Human OMKO1 Drug-resistant
P. aeruginosa
A single application of phage OMKO1 and
ceftazidime, the infection appeared to
resolve with no signs of recurrence.
Schooley
et al68









This clinical study showed that systemic
administration of the bacteriophage therapy
through intravenous administration was
cured A. baumannii infection in anatomic
sites.
Ooi et al69 2019 Australia Human AB-SA01 MDR S. aureus
infections
Results showed that treatment was well
performed, no adverse effects were
observed
Letkiewic73 2009 Poland Human PT Chronic E. faecalis
Prostatitis
Phage eliminated infection, and improved
patients with lack of early disease
recurrence.
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cassettes in Bacillus cereus, which undergo extensive hori-
zontal gene transfer and provide complete phage resistance to
a wide variety of phages, containing lytic and temperate
ones.124 Quorum-sensing regulation as a defense mechanism
in pathogens allows shifting between various phage protec-
tion mechanisms based on population cell density. Under
high-cell-density conditions, quorum sensing mediated
down-regulation of phage receptor adsorption and bacteria
unsusceptible to phage infection, but when the density of
cells was low, quorum sensing did not affect the phage
receptor expression and the cells were quite susceptible to
phage.125,126 DISARM (defense island system associated
with restriction–modification), widely spread in bacteria
and archaea, is a new type of anti-phage mechanism that
restricts incoming phage DNA and thereby confront viruses
of various families of tailed phages. DISARM is a system
made up of five genes, one for DNA methylation and four
other genes annotated as a helicase domain, a phospholipase
D domain, a DUF1998 domain and a gene of unknown
function.127 Abortive infection (Abi) systems are mechan-
isms of innate immunity in bacteria that limit phage dissemi-
nation by blocking phage multiplication and cause premature
bacterial cell death upon phage infection. Accordingly, the
goal of this “altruistic suicide” strategy is killing the infected
cells and decreasing the phage population at minimum
meanwhile protecting the uninfected surrounding cells.128
Also, some bacterial chromosomal and plasmid toxin-
antitoxin (TA) systems are subgroups of Abi systems that
play a role in phage defense.129,130 The phage-inducible
chromosomal islands (PICIs) of Gram-positive bacteria are
genetic elements with highmobility and substantial contribu-
tion to horizontal gene transfer, host adaptation, virulence,
and phage parasites. These mobile genetic elements have the
capacity to interfere with the reproduction of certain phages.
They were initially identified in S. aureus, but now these
elements are thought to occur widely in Gram-positive bac-
teria such as Lactococci, Pneumococci, E. faecalis, and
Streptococci.131,132 A PICI-like element with the ability to
inhibit a virulent phage has also been detected recently.
Although the basis of its mechanism of action is still
unknown, it is certain that such elements are very common
among the Lactococci, V. cholera, and Streptococci.131,133
How Phages Overcome Bacterial
Bacteriophage Resistance
The combat for survival between bacteria and the phages that
infect them has led to the evolution of multiple bacterial
defense systems and phage-encoded antagonists of these
systems. In contrast to the various known anti-phage systems
of bacteria, the counteracting mechanisms of phages are
poorly understood. Some reports have pointed to several of
these mechanisms that allow phages to evade.133–135 Phages
with the potential of acquiring new receptors tropism can
alter their receptor-binding protein, this means that when
a host receptor changes to a mutated form, phages can
recognize the modified receptor structure and in this way
they counteract disturbance in receptors for phage adsorp-
tion. When a surface component like a capsule or another
exopolysaccharide (EPS) compound conceal bacterial recep-
tors, phages can increase binding to the receptor by hydro-
lyzing these barriers using different enzymes such as
endosialidase, hyaluronanlyase, exopolysaccharide degrad-
ing enzyme, and alginase. When the host receptors are
expressed only under particular environmental conditions,
phase are variable or expressed only during a certain growth
phase, encoding receptor-binding proteins with variable spe-
cificities enables phages to increase the chance of infecting
their host. Accordingly, encoding multiple receptor-binding
proteins with varying specificity leads to an expansion of
host range.48,136,137 To escape the notable variety of R–M
systems, phages utilize types of antirestriction strategies,
which can be broadly classified into passive and active







CRISPR Degradation of the injected phage DNA
Genetic mutation Disturbance in receptors for phage
adsorption
RNases Interfere with phage adsorption
Super infection exclusion
(Sie) systems
Prevent the entry of phage DNA into
bacterial cytoplasm
BREX defense system Block phage DNA replication
Quorum sensing defense Alternate between different phage




Blocking phage multiplication and cause
premature bacterial cell death upon
phage infection




Interfere with the reproduction of
phages
PICI-like element The activity is not yet known
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mechanisms. When a phage DNA enters the host, passive
mechanisms protect the phage DNA if the host methyltrans-
ferase acts rapidly and modifies the phage DNA before
recognition by the endonuclease. Although a modified
phage genome can replicate in the host, it is recognized as
a foreign phage in other cells, except in the cells that express
the same R–M system. Active mechanisms of phage evasion
occur when the phage can co-inject proteins with its genome
to attach straightly to the phage DNA and mask restriction
sites or binds to both the methyltransferase and the endonu-
clease of R–M system and control of its activity. In addition,
multiple encoding modification genes with different advan-
tages for example, methylation, have also been demonstrated
in phages. These modification genes protect phages from the
activity of the host endonuclease and the protection occurs in
all hosts. Five distinct anti-CRISPR genes are presented in
P. aeruginosa temperate phages. These genes encode a small
protein, which is delivered to the cell along with the viral
genome, or it can immediately neutralize the immune system
of the host by interfering with the formation or action of the
CRISPR–Cas ribonucleo protein.138 The mutation is another
anti-CRISPR mechanism that does not significantly impair
phage infectivity or fitness. As a result, this mutation is
a single-nucleotide substitution event on protospacer-
adjacent motif also known as the seed sequence for
CRISPR. Some phages harbor acr genes, which antagonize
bacterial CRISPR-Cas immune systems. Acr is a phage-
encoded protein that interferes with the CRISPR–Cas system
by binding to the components of its machinery.139,140 The
phage-encoded CRISPR-Cas system is a system used for
counteracting a phage inhibitory chromosomal island of the
bacterial host. Phages can hijack bacterial CRISPR–Cas
systems to promote their own multiplication, which allows
the phage to complete its lytic cycle.141 Unlike other systems,
Abi systems induce death of the host cell, but some phages
can bypass the Abi mechanism through mutations in genes
involved in nucleotide metabolism. Also, phages can encode
a pseudo-antitoxin molecule that functionally substitutes the
bacterial antitoxin, consequently neutralizes toxin activity
and eludes host death.136
Disadvantages of Phage Therapy
and the Need for Further Studies
In spite of several advantages noted yet for bacterio-
phages, they have some limitations. Phages may be
resisted by bacteria. Some of the resistance mechanisms
developed by bacteria against phages have already been
identified.142 Another issue regarding the phage therapy
is that the bacteriophages are potentially able to transfer
the antibiotic-resistance genes or other bacterial viru-
lence from a bacterium to another, which are carried
through generalized transduction.143 Although there are
standardized methods for the production of phage cock-
tails, clear official guidelines are not available. The
phage immunogenicity is another source of concern,
that is, the patient’s immune system may recognize the
phage as a potential invader and therefore rapidly
remove it from the systemic circulation, which may
result in a concentration lower than its effective
dose.27 The genome of the majority of phages has
been unraveled, although, the function of many of
these genes is still unknown.144 At the end of its anti-
bacterial action, lytic phages induce rapid lysis of
a large number of bacteria in vivo that may lead to the
release of endotoxins and super antigens from Gram-
negative bacteria. This release of endotoxins may induce
an inflammatory cascade that eventually lead to
a multiple organ failure.44 In scientific works, extrapola-
tion of findings of in vitro studies to in vivo situations
and even generalization of findings from one in vivo
situation to another is difficult and they must be inter-
preted with caution.145 Since the phages are host-
specific agents, the exact host bacterium must be identi-
fied, because the strain specificity is rather than species
specificity, and it can increase difficulty when preparing
phages for highly diverse bacterial variants.144 Table 1
summarizes different disadvantages of phage therapy.
The specificity of the phage against pathogens can be
both advantageous and disadvantageous for phage ther-
apy. Because of this characteristic of phages, a bacterial
infectious agent must first be isolated and cultured using
standard microbiological diagnostic methods and fully
identified, then a specific bacteriophage solution is
administered to the patient. Accordingly, the process of
diagnosing an infectious agent in clinical microbiology
laboratories is very time-consuming and has limitations
in health care settings.27 Furthermore, in the treatment
of infectious diseases, lytic phages should be used
exclusively because lysogenic phages delay the lysis of
bacteria and prevent the effect of phages on acute
infections.146 On the other hand, phage treatment in
most countries except Poland and Switzerland is not
covered by public health insurance, which is a major
financial problem for patients.147,148 At present, phages
are not accepted as pharmaceutical drugs, and current
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European pharmacological regulations, definitions and
standards are not sufficiently adapted to phage prepara-
tions. Therefore, an international nonprofit called P.H.A.
G.E (for Phages for Human Application Group Europe)
was developed by a Belgian research team and some
members of the Pasteur Institute in Paris to create
a specific framework for the use of bacteriophages.27
In spite of these undesirable properties, applying phages
for the treatment of resistant bacteria is still a very good
alternative, because their therapeutic effects have been
approved in several studies. So, it can be considered as
a good treatment option for resistant infections, because
it may be the only option available for rescuing patients.
Conclusion and Perspectives
Infrequency of new antibiotics against MDR, XDR,
PDR, and resistant forms of bacteria, such as biofilm,
in nosocomial infections renders bacteriophages as
potential new tools for treatment. There is an increased
demand for bacteriophage-based therapy in such resis-
tant bacteria and phage cocktails are increasingly used
against bacteria with phage resistance mechanism. The
results of animal studies have been in line with in vitro
findings. Different routes of administration have been
demonstrated for using in bacteriophage therapy.
A major restriction is that no well-designed clinical
survey has been performed, so, physicians and research-
ers cannot evade bacteriophages in the search as a novel
therapy for infectious diseases. Nevertheless, a better
development of phage therapy as a usual alternative to
strictly chemical-based treatment of bacterial infections
in humans will require much greater enterprise than that
has so far been the case. Therefore, the bacteriophage
may become one of the biggest hopes in the future for
the treatment of resistant bacteria that do not respond to
the treatment. However, to achieve commercial applica-
tions in medical problems, more research and develop-
ment are needed.
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